drugset / Trial / NCT00622609
Anti-MAG First Administration to Human
RandomizedParallel-groupSingle-blindTreatment
Summary
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury, which occurs in spinal cord injury or stroke.
Timeline
- Start
- 2007-08-01
- Primary completion
- 2009-04-09
- Completion
- 2009-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK249320A | Monoclonal antibody | 0.04 mg/kg | Intravenous |
| Subject | GSK249320A | Monoclonal antibody | 0.4 mg/kg | Intravenous |
| Subject | GSK249320A | Monoclonal antibody | 1.2 mg/kg | Intravenous |
| Subject | GSK249320A | Monoclonal antibody | 3.5 mg/kg | Intravenous |
| Subject | GSK249320A | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | GSK249320A | Monoclonal antibody | 25 mg/kg | Intravenous |